

All Providers

- 1 Did You Know? - Provider Web Portal Password Reset
- 1 National Correct Coding Initiative (NCCI) Notification of Quarterly Updates
- 1 Provider Enrollment Requirement
- 2 Update to Provider Participation Rule Section 8.130

Clinics, Non-Physician Practitioners

- 2 Coverage of Electrolysis (Permanent Hair Removal)

Dialysis Providers

- 2 Home Dialysis for Recipients of Emergency Medicaid Services with End-Stage Renal Disease (ESRD)

HCBS Providers

- 3 American Rescue Plan Act (ARPA) Billing for Home and Community-Based (HCBS) Services

Hospice Providers

- 4 Hospice Claims Selected for Potential Recovery Audit Contractor (RAC) Review

Hospital Providers

- 5 General Updates

Hospitals, FQHC, RHC, IHS, Physician Services, Home Health, Managed Care Plans, Nursing Facilities

- 6 COVID-19 Monoclonal Antibody Infusions

Pharmacy Providers

- 15 Reminder to Update Fax Numbers

Pharmacies & All Medication-Prescribing Providers

- 15 Health First Colorado Preferred Drug List (PDL) Announcement of Preferred Products
- 18 Pharmacy and Therapeutics (P&T) Committee Meeting

Physician-Administered Drugs (PADs) Providers

- 18 Prior Authorization (PA) Update

Physician Services

- 20 Upcoming Diabetes Webinar Opportunity

Radiology and Imaging

- 21 Temporary Removal of Prior Authorization Requests for Specific Diagnostic Imaging Codes

Provider Billing Training Sessions

- 21 December 2021 and January 2022 Provider Billing Webinar-Only Training Sessions

All Providers

Did You Know?

All delegate accounts in the [Provider Web Portal](#) can be reset by the administrator within the provider organization. Users with a delegate status must refer to the administrator for a password reset. The [Provider Services Call Center](#) can only reset administrative passwords.

The administrative account gives the user full access to the functionality available within the Provider Web Portal. Providers may have one account administrator assigned.

Refer to the [Administrative Password Reset Process document](#) on the [Quick Guides web page](#) for step-by-step instructions.

National Correct Coding Initiative (NCCI) Notification of Quarterly Updates

Providers are encouraged to monitor [Centers for Medicare & Medicaid Services \(CMS\) website](#) for updates to NCCI rules and guidelines. Updates to the procedure-to-procedure (PTP) and medically unlikely edit (MUE) files are completed quarterly with the next file update available January 2022. For more information, visit the [CMS National Correct Coding Initiative Edits web page](#).

Provider Enrollment Requirement

Providers are reminded that the Affordable Care Act (ACA) requires physicians and other eligible practitioners to enroll in Health First Colorado (Colorado's Medicaid program). This applies to all rendering, attending, and ordering, prescribing and referring (OPR) providers.

All National Provider Identifiers (NPIs) listed on a claim must be enrolled with Health First Colorado.

Contact the [Provider Services Call Center](#) to confirm the enrollment status of an individual provider prior to billing.

Update to Provider Participation Rule Section 8.130

The Provider Participation rule, [Section 8.130](#), will be updated effective December 1, 2021. Please review the updated rule which includes a change to the provider record retention requirement from 6 years to 7 years. All records dated on or after December 1, 2015, must now be retained for 7 years.

Contact Sarah Geduldig at Sarah.Geduldig@state.co.us with any questions.

Clinics, Non-Physician Practitioners

Coverage of Electrolysis (Permanent Hair Removal)



Electrolysis permanent hair removal (Current Procedural Terminology [CPT] 17380) is a covered benefit for members meeting the eligibility requirements in the [Transgender Services Billing Manual](#) when used to treat a surgical site.

Providers must be enrolled in Health First Colorado to receive payment for these services. Providers interested in offering electrolysis to Health First Colorado members are encouraged to reach out to the Department of Health Care Policy & Financing (the Department) for more information.

Contact Christopher Lane at Christopher.Lane@state.co.us with any questions.

Dialysis Providers

Home Dialysis for Recipients of Emergency Medicaid Services with End-Stage Renal Disease (ESRD)

Effective January 1, 2022, home dialysis will be a covered benefit for recipients of Emergency Medicaid Services (EMS) with End-Stage Renal Disease (ESRD).

As of February 1, 2019, ESRD has been considered to be an emergency medical condition as defined at 10 CCR 8.100.3.G.1.g.vii; 42 U.S.C. § 1396b(v)(3); and Colorado Revised Statutes § 24-76.5-102(1). For services provided to an EMS recipient, a provider must certify the

presence of an emergency medical condition and indicate on claim forms that services are for a medical emergency. Coverage is limited to care and services that are necessary to treat the immediate emergency medical conditions and does not include prenatal care or follow-up care.

To indicate an emergency when billing:

- CMS-1500/835P: Use field 24C (EMG)
- UB-04/837I: Indicate Admission Type 1 (Emergency) or 5 (Trauma)

To indicate services were performed at home (after January 1, 2022):

- Condition Code 74

Contact Raine Henry at Raine.Henry@state.co.us with policy questions.



Home and Community-Based Services (HCBS) Providers

American Rescue Plan Act (ARPA) Billing for Home and Community-Based (HCBS) Services

Due to the complex nature of temporary rate increases effective retroactively to April 1, 2021, and July 1, 2021, for HCBS services related to the American Rescue Plan Act (ARPA), all rate discrepancies present in the Colorado interChange and Bridge systems are in the process of being identified and corrected. Any claims that were not paid at the correct rate will be reprocessed via mass adjustment as soon as possible.



Claims adjustments will only apply to those claims manually adjusted or submitted following the implementation of the ARPA rate changes and will not be applicable to claims solely based on reimbursement of the previous rate. Providers will need to continue the manual adjustment process in order to receive the additional reimbursement related to these date spans. The fee schedules posted on the [Provider Rates and Fee Schedule web page](#) under the [HCBS American Rescue Plan Act Rate Schedule](#) heading have been updated to reflect any changes.

Home & Community-Based Service (HCBS), Home Health, Private Duty Nursing, and Outpatient Therapy Providers

Electronic Visit Verification (EVV) Claim Edit Timeline

[Electronic Visit Verification](#) (EVV) is a technology solution which verifies that home or community-based service visits occur. Refer to the [EVV Types of Service - Service Code Inclusion Section](#) located in the EVV Program Manual to determine if an agency requires EVV.

A tiered implementation strategy is being utilized to familiarize providers with the use of EVV and it has been mandated by [10 CCR 2505-10 8.001](#) since August 3, 2020. Beginning **February 1, 2022**, all claims requiring the use of EVV will encounter a pre-payment review. **Claims without necessary EVV records will deny.**

Prior to February 1, 2022, claims that are missing EVV or have incomplete EVV records will show in the provider's Remittance Advice (RA) as Explanation of Benefits EOB 3054 "EVV Record Required and Not Found" and the claim will pay. Effective February 1, 2022, claims that are missing EVV or have incomplete EVV records will show in the provider's RA as EOB 3054 "EVV Record Required and Not Found" and the claim will deny. Providers not making an earnest effort to collect EVV records are currently experiencing suspension of EVV-required claims. Information on the suspension of claims of non-utilizers can be found in [HCPF Operational Memo \(OM\) 21-044](#).

Review [HCPF OM 21-075](#) and visit the [EVV web page](#) for additional information on the claim edit timeline. Monthly stakeholder meetings are hosted to discuss EVV and participation from all stakeholders is welcomed.

Contact Sandata Technologies by phone at 855-871-8780 or email cocustomercare@sandata.com with questions regarding the State EVV Solution or connecting a Provider Choice EVV System.

Contact EVV@state.co.us with all other questions.

Hospice Providers

Hospice Claims Selected for Potential Recovery Audit Contractor (RAC) Review

Health Management Systems, Inc. (HMS) has been contracted to serve as the Recovery Audit Contractor (RAC) to conduct post-payment reviews of claims submitted for fee-for-service and managed care services. This is a federally mandated contract program. In February 2018, HMS began reviews to identify overpayments and assist in recovering any overpayments made to providers for Health First Colorado fee-for-service and Child Health Plan *Plus* (CHP+) medical claims.



Hospice claims have recently been selected for a potential RAC review. HMS and the Department have an online pre-recorded training session to learn about the RAC process and the HMS RAC Provider Portal.

All Hospice Chief Financial Officers (CFOs), Medicaid Billing Managers, and Accounts Receivable Specialists are encouraged to attend.

HMS has a pre-recorded training to allow providers to participate at their convenience. HMS will also be offering two webinars where the recording will be played with time for questions and answers following the training. The dates and times of these webinars are below:

- **Monday 12/6/2021 at 11:00 a.m. MT**
[Register for this training and Q&A Session](#)
- **Tuesday 12/7/2021 at 2:00 p.m. MT**
[Register for this training and Q&A Session](#)

The recorded webinar is located on the Recovery Audit Contractor (RAC) Program web page as are other resources and information available for providers. Click below to access the pre-recorded webinar:

[Clinical Retrospective Presentation Process, Hospice \(Webinar\)](#)

Visit the [Recovery Audit Contractor \(RAC\) Program web page](#) for more information.

Hospital Providers

General Updates

All Hospital Providers

Hospital Stakeholder Engagement Meetings

Bi-monthly Hospital Engagement meetings will continue to be hosted to discuss current issues regarding payment reform and operational processing. [Sign up to receive the Hospital Stakeholder Engagement Meeting newsletters.](#)


The All-Hospital Engagement meeting is scheduled for [Friday, January 14, 2021, from 1:00 p.m. - 4:00 p.m. MT](#) and will be hosted virtually.

Visit the [Hospital Stakeholder Engagement Meeting web page](#) for more details, meeting schedules and past meeting materials. Calendar Year 2022 meetings have been posted.

Update to Version 3.16 of Enhanced Ambulatory Patient Grouping (EAPG) Methodology

The Department has been collaborating with its vendors and hospital stakeholders over the last year preparing for the implementation of a new version of the EAPG (3.16) methodology which calculates payment for outpatient hospital services. This new version of EAPGs will be effective January 1, 2022, and will require both Medical Services Board and State Plan authority for implementation. The base rate methodology for maintaining revenue neutrality

amongst hospitals and their groups, which was shared in the November Stakeholder Meeting, and the relative weights Colorado intends to use for EAPG payments have been posted to the [Outpatient Hospital Payment web page](#) for review.



Reference the meeting notes contained on the [Hospital Stakeholder Engagement Meeting web page](#) for more information regarding the update to version 3.16.

Contact Andrew Abalos at Andrew.Abalos@state.co.us and Tyler Samora at Tyler.Samora@state.co.us with any questions regarding this update.

Rural Health Clinics

Bi-monthly Rural Health Clinic Engagement meetings will continue to be hosted to discuss current issues regarding payment reform and operational processing.

The next Rural Health Clinic Engagement meeting is scheduled for [Thursday, January 13, 2022, from 12:30 p.m. to 1:30 p.m. MT](#) and will be hosted virtually on Zoom.

Visit the [Rural Health Clinic Engagement Meeting web page](#) for more details, meeting schedules and past meeting materials.

Contact Erin Johnson at Erin.Johnson@state.co.us with any questions or topics to be discussed at future meetings. Advanced notice will provide the Rates team time to bring additional Department personnel to the meetings to address different concerns.

Hospitals, Federally Qualified Health Clinic (FQHC), Rural Health Clinic (RHC), Indian Health Services (IHS), Physician Services, Home Health, Managed Care Plans, Nursing Facilities

COVID-19 Monoclonal Antibody Infusions

Monoclonal antibody products to treat Coronavirus Disease 2019 (COVID-19) help the body fight the virus or slow the virus's growth. Beginning March 11, 2021, Health First Colorado covers these treatments without member cost sharing when used as authorized or approved by the Food and Drug Administration (FDA).

The following table includes the monoclonal antibody therapies that are available under FDA emergency use authorization (EUA). Additional information regarding these therapies and EUAs can be found on the FDA [Emergency Use Authorization web page](#).

Monoclonal Antibody	Authorized Use	FDA Fact Sheet
<p>REGEN-COV (casirivimab and imdevimab, administered together)</p>	<ol style="list-style-type: none"> 1. Treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older, weighing at least 40kg) when the following apply: <ul style="list-style-type: none"> • The patient has a positive COVID-19 test result • The patient is at high risk for progression to severe COVID-19, including hospitalization, or death 2. Post-exposure prophylaxis for COVID-19 in adults and pediatric patients (12 years of age and older, weighing at least 40kg) who are at high risk for progression to severe COVID-19, including hospitalization or death <p>AND</p> <ul style="list-style-type: none"> • Not fully vaccinated or not expected to mount adequate immune response to COVID-19 vaccination AND • Exposed to COVID-19 positive close contact per CDC criteria or at high risk of exposure to COVID-19 due to COVID-19 positivity in other individuals within the same institutional setting 	<p>Fact Sheet, last updated November 1, 2021</p>

Monoclonal Antibody	Authorized Use	FDA Fact Sheet
Bamlanivimab and Etesevimab, administered together	<ol style="list-style-type: none"> 1. Treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older, weighing at least 40kg) when the following apply: <ul style="list-style-type: none"> • The patient has a positive COVID-19 test result • The patient is at high risk for progression to severe COVID-19, including hospitalization or death 2. Post-exposure prophylaxis for COVID-19 in adults and pediatric patients (12 years of age and older, weighing at least 40kg) who are at high risk for progression to severe COVID-19, including hospitalization or death AND <ul style="list-style-type: none"> • Not fully vaccinated or not expected to mount adequate immune response to COVID-19 vaccination AND • Exposed to COVID-19 positive close contact per CDC criteria or at high risk of exposure to COVID-19 due to COVID-19 positivity in other individuals within the same institutional setting 	Fact Sheet , last updated September 16, 2021

Monoclonal Antibody	Authorized Use	FDA Fact Sheet
Sotrovimab	1. Treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older, weighting at least 40kg) when the following apply: <ul style="list-style-type: none"> • The patient has a positive COVID-19 test result • The patient is at high risk for progression to severe COVID-19, including hospitalization or death 	Fact Sheet , last updated November 3, 2021
Tocilizumab (Actemra)	Treatment of hospitalized COVID-19 positive adults and pediatric patients (2 years of age and older) who are receiving systemic corticosteroids and require supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO)	Fact Sheet , last updated June 24, 2021

Health care providers may administer these monoclonal antibody therapies only in settings where they have both of the following:

- Immediate access to medications to treat a severe infusion reaction, such as anaphylaxis
- The ability to activate the emergency medical system (EMS)

The following tables may be used as a procedure code reference during the applicable EUA.

COVID-19 Monoclonal Antibody Therapy Treatment Administration Methods Billing:

Product	EUA Effective & Revocation Date(s)	Specific Code	Administration Code
Eli Lilly and Company's Antibody Bamlanivimab (LY-CoV555)	November 10, 2020 - April 16, 2021 Note: On April 16, 2021, the FDA revoked the EUA for bamlanivimab when administered alone.	Q0239 Long descriptor: Injection, bamlanivimab-xxxx, 700 mg Short descriptor: Bamlanivimab-xxxx	M0239 Long Descriptor: Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring Short Descriptor: Bamlanivimab-xxxx infusion
Regeneron's Antibody casirivimab and imdevimab (REGN-COV2)	July 30, 2021 - TBD	Q0240 Long descriptor: Injection, casirivimab and imdevimab, 600mg Short descriptor: Casirivi and imdevi 600mg	M0240 Long descriptor: Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring, subsequent repeat doses Short descriptor: Casiri and imdev repeat
Regeneron's Antibody casirivimab and imdevimab (REGN-COV2)	July 30, 2021 - TBD	Q0240 Long descriptor: Injection, casirivimab and imdevimab, 600mg Short descriptor: Casirivi and imdevi 600mg	M0241 Long descriptor: Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence, this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency, subsequent repeat doses

Product	EUA Effective & Revocation Date(s)	Specific Code	Administration Code
			Short descriptor: Casiri and imdev repeat hm
Regeneron's Antibody casirvimab and imdevimab (REGN-COV2)	November 21, 2020 - TBD	<p>Q0243</p> <p>Long descriptor: Injection, casirvimab and imdevimab, 2400 mg</p> <p>Short descriptor: Casirvimab and imdevimab</p> <p>Q0244 (Code effective 06/03/2021 and reflects updated dosing regimen)</p> <p>Long descriptor: Injection, casirvimab and imdevimab, 1200 mg</p> <p>Short descriptor: Casirivi and imdevi 1200 mg</p>	<p>M0243</p> <p>Long Descriptor: Intravenous infusion or subcutaneous injection, casirvimab and imdevimab includes infusion or injection, and post administration monitoring</p> <p>Short Descriptor: Casirivi and imdevi inj</p>
Regeneron's Antibody casirvimab and imdevimab (REGN-COV2)	November 21, 2020 - TBD Note: While the product EUA was issued on November 21, 2020, this administration code is effective May 6, 2021.	<p>Q0243</p> <p>Long descriptor: Injection, casirvimab and imdevimab, 2400 mg</p> <p>Short descriptor: Casirvimab and imdevimab</p>	<p>M0244</p> <p>Long Descriptor: Intravenous infusion or subcutaneous injection, casirvimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the</p>

Product	EUA Effective & Revocation Date(s)	Specific Code	Administration Code
		Q0244 (Code effective 06/03/2021 and reflects updated dosing regimen) Long descriptor: Injection, casirivimab and imdevimab, 1200 mg Short descriptor: Casirivi and imdevi 1200 mg	hospital during the COVID-19 public health emergency ¹ Short Descriptor: Casirivi and imdevi inj hm
Eli Lilly and Company's Antibody Bamlanivimab and Etesevimab	February 9, 2021 - TBD	Q0245 Long descriptor: Injection, bamlanivimab and etesevimab, 2100 mg Short descriptor: Bamlanivimab and etesevima	M0245 Long Descriptor: Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring Short Descriptor: Bamlan and etesev infusion
Eli Lilly and Company's Antibody Bamlanivimab and Etesevimab	February 9, 2021 (reissued on February 25, 2021) - TBD Note: While the product EUA was issued on February 9, 2021, this administration code is effective May 6, 2021.	Q0245 Long Descriptor: Injection, bamlanivimab and etesevimab, 2100 mg Short Descriptor: Bamlanivimab and etesevima	M0246 Long Descriptor: Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency ¹ Short Descriptor: Bamlan and etesev infus home

Product	EUA Effective & Revocation Date(s)	Specific Code	Administration Code
GlaxoSmithKline's Antibody Sotrovimab	May 26, 2021 - TBD	Q0247 Long descriptor: Injection, sotrovimab, 500 mg Short descriptor: Sotrovimab	M0247 Long Descriptor: Intravenous infusion, sotrovimab, includes infusion and post administration monitoring Short Descriptor: Sotrovimab infusion
GlaxoSmithKline's Antibody Sotrovimab	May 26, 2021 - TBD	Q0247 Long descriptor: Injection, sotrovimab, 500 mg Short descriptor: Sotrovimab	M0248 Long Descriptor: Intravenous infusion, sotrovimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency ¹ Short Descriptor: Sotrovimab inf, home admin
Genentech's Antibody Tocilizumab	June 24, 2021 - TBD	Q0249 Long descriptor: Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or	M0249 Long Descriptor: Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, includes infusion and post

Product	EUA Effective & Revocation Date(s)	Specific Code	Administration Code
		extracorporeal membrane oxygenation (ECMO) only, 1 mg Short descriptor: Tocilizumab for COVID-19	administration monitoring, first dose Short Descriptor: Adm Tocilizu COVID-19 1st
Genentech's Antibody Tocilizumab	June 24, 2021 - TBD	Q0249 Long descriptor: Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, 1 mg Short descriptor: Tocilizumab for COVID-19	M0250 Long descriptor: Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, includes infusion and post administration monitoring, second dose Short descriptor: Adm Tocilizu COVID-19 2nd

Providers should only bill Health First Colorado for the administration procedure codes and should not include the monoclonal antibody-specific procedure codes on the claim when doses of either therapy are provided without charge from the Federal government. If codes are billed for the monoclonal antibody(ies), the line(s) may pay at zero or be denied. This information is subject to change dependent on the COVID-19 public health emergency declaration.

If a Health First Colorado member is attributed to Denver Health Medicaid Choice or Rocky Mountain Health Plan PRIME, the monoclonal antibody infusion administration procedure codes should be billed to the managed care organization.


Current reimbursement rates can be found on the [Provider Rates & Fee Schedule web page](#).

Contact Felecia Gephart at Felecia.Gephart@state.co.us or Morgan Anderson at Morgan.Anderson@state.co.us with any questions.

Pharmacy Providers

Reminder to Update Fax Numbers

Pharmacy providers are encouraged to ensure their fax numbers are accurate and current to receive important pharmacy fax blasts. Many pharmacies either do not have a fax number on file or have a corporate fax number on record. Refer to the [Provider Maintenance - Provider Web Portal Quick Guide](#) available on the [Quick Guides web page](#) for more information on updating the fax number.



Pharmacies & All Medication-Prescribing Providers

Health First Colorado Preferred Drug List (PDL) Announcement of Preferred Products

The following will be the preferred products for the PDL drug classes listed below effective January 1, 2022.

Non-Steroidal Anti-Inflammatories (NSAIDs) - Oral

Preferred products: Celecoxib, Diclofenac Sodium EC/DR, Diclofenac Potassium, Ibuprofen tablet/suspension (Rx), Indomethacin, Ketorolac tab, Meloxicam tab, Nabumetone, Naproxen, Sulindac

Non-Steroidal Anti-Inflammatories (NSAIDs) - Non-Oral

Preferred products: Diclofenac 1% gel (Rx), Diclofenac solution, Voltaren gel (Rx)

Antibiotics, Inhaled

Preferred products: Tobramycin inhalation solution, Cayston

Antiherpetic Agents

Preferred products: Acyclovir capsule/ointment/suspension/tablet, Denavir, Famciclovir, Valacyclovir, Zovirax (BNR) cream

Fluoroquinolones - Oral

Preferred products: Cipro suspension, Ciprofloxacin suspension/tablet, Levofloxacin tab

Hepatitis C Virus Treatments

Preferred products: Epclusa 200-50mg tablet, Harvoni 45-200mg tablet, Harvoni pellets, Ledipasvir/Sofosbuvir 90-400mg tablet (generic Harvoni - *Asegua only*), Mavyret, Ribavirin capsule/tablet, Sofosbuvir/Velpatasvir 400-100mg tablet (generic Epclusa - *Asegua only*), Vosevi

Human Immunodeficiency Virus (HIV) Treatments

Preferred products: All products preferred

Pulmonary Arterial Hypertension Agents

Preferred products: Ambrisentan, Epoprostenol vial, Flolan vial, Orenitram ER, Revatio (BNR) suspension, Sildenafil (generic Revatio) tablet, Tracleer (BNR) 62.5 mg, 125 mg tablet, Tadalafil (generic Adcirca), Ventavis

Newer Generation Antidepressants

Preferred products: Bupropion 75mg, 100mg tablet, Bupropion ER/SR 100mg, 150mg, 200mg, 300mg tablet, Citalopram, Desvenlafaxine (generic Pristiq), Duloxetine (generic Cymbalta), Escitalopram, Fluoxetine capsule/solution, Fluvoxamine IR, Mirtazapine, Paroxetine, Sertraline, Trazodone, Venlafaxine IR, Venlafaxine ER capsule

Monoamine Oxidase Inhibitors (MAOIs)

Preferred products: No preferred agents

Tricyclic Antidepressants (TCAs)

Preferred products: Amitriptyline, Doxepin 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg capsule, Doxepin solution, Imipramine HCl, Nortriptyline

Triptans and Other Migraine Treatments

Preferred products: Eletriptan, Imitrex (BNR) nasal spray, Naratriptan, Rizatriptan, Sumatriptan tablet/vial, Zolmitriptan nasal spray - *Amneal only*

Antipsoriatics

Preferred products: Acitretin capsule, Calcipotriene solution, Dovonex (BNR) cream, Taclonex (BNR) ointment/Scalp suspension

Topical Immunomodulators

Preferred products: Elidel (BNR), Protopic (BNR)

Topical Steroids - Low Potency


Preferred products: Derma-smoothe-FS (BNR), Desonide cream/ointment, Hydrocortisone (Rx) cream/lotion/ointment, Fluocinolone cream

Topical Steroids - Medium Potency

Preferred products: Betamethasone dipropionate lotion, Betamethasone Valerate cream/ointment, Fluticasone cream/ointment, Mometasone Furoate cream/ointment/solution, Triamcinolone cream/ointment/lotion

Topical Steroids - High Potency

Preferred products: Betamethasone Dipropionate-Propylene Glycol Cream, Fluocinonide cream/gel/ointment/solution



Topical Steroids - Very High Potency

Preferred products: Betamethasone Dipropionate-Propylene Glycol Ointment, Clobetasol cream/gel/ointment/solution

Antiemetics - Oral

Preferred products: Diclegis (BNR), Meclizine (Rx), Metoclopramide solution/tablet, Ondansetron, Prochlorperazine, Promethazine syrup/tablet, Trimethobenzamide

Antiemetics - Non-Oral

Preferred products: Prochlorperazine suppository, Promethazine 12.5 mg and 25 mg suppository, Scopolamine patch

H. Pylori Treatments

Preferred products: Pylera

Pancreatic Enzymes

Preferred products: Creon, Pancreaze, Zenpep

Proton Pump Inhibitors

Preferred products: Esomeprazole Magnesium capsule, Lansoprazole capsule/solutab, Nexium (BNR) packet, Omeprazole capsule, Pantoprazole tablet

Non-Biologic Ulcerative Colitis Agents - Oral

Preferred products: Apriso (BNR), Lialda (BNR), Pentasa, Sulfasalazine

Non-Biologic Ulcerative Colitis Agents - Non-Oral

Preferred products: Mesalamine suppository (generic Canasa), Mesalamine sulfite-free (generic sf-Rowasa) enema

Immune Globulins

Preferred products: Cuvitru, Gammagard liquid, Gammaked, Gammaplex, Gamunex-C, Hizentra syringe/vial, Privigen

Newer Generation Antihistamines

Preferred products: Cetirizine (OTC/Rx) solution/tablet, Desloratadine, Levocetirizine tablet (OTC), Loratadine solution/tablet (OTC)

Antihistamine/Decongestant Combinations

Preferred products: Loratadine-Pseudoephedrine tablet (OTC)

Intranasal Rhinitis Agents

Preferred products: Azelastine 0.15%, Azelastine 137 mcg, Budesonide (OTC), Fluticasone (Rx), Ipratropium, Triamcinolone (OTC)

Leukotriene Modifiers

Preferred products: Montelukast chewable tablet/tablet

Methotrexate Agents

Preferred products: Methotrexate vial, tablet

Targeted Immune Modulators

Preferred products: Enbrel, Humira, Kevzara, Otezla, Taltz, Xeljanz IR

Epinephrine Products

Preferred products: Epipen (BNR), Epipen Jr (BNR)

Newer Hereditary Angioedema Agents

Preferred products: Berinert, Haegarda, Icatibant

Antihyperuricemics

Preferred products: Allopurinol, Colcrys (BNR), Probenecid, Probenecid/Colchicine

Respiratory Agents - Inhaled Anticholinergics & Combinations

Preferred products: Anoro Ellipta, Atrovent HFA, Combivent Respimat, Ipratropium, Ipratropium-Albuterol nebulas, Spiriva Handihaler/Respimat

Respiratory Agents - Short-Acting Beta-Agonists

Preferred products: Albuterol nebulas, ProAir HFA (BNR), Ventolin HFA (BNR)

Respiratory Agents - Long-Acting Beta-Agonists

Preferred products: Serevent Diskus

Respiratory Agents - Inhaled Corticosteroids & Combinations

Preferred products: Advair (BNR) Diskus, Advair HFA, Asmanex, Budesonide respules, Dulera, Flovent Diskus/HFA, Pulmicort Flexhaler, Symbicort (BNR)

Respiratory Agents - Phosphodiesterase Inhibitors

Preferred products: No preferred products

Pharmacy and Therapeutics (P&T) Committee Meeting

Tuesday, January 11, 2022

1:00 p.m.-5:00 p.m. MT

303 E 17th Ave (meeting to be held virtually, not in person)

Agenda and meeting information can be found at the [Pharmacy and Therapeutics \(P&T\) Committee web page](#).



Physician-Administered Drugs (PADs) Providers

Prior Authorization (PA) Update

A select number of physician-administered drugs (PADs), listed below, will be subject to prior authorization (PA) requirements, no earlier than **January 1, 2022**. When a specific implementation date is known, the Department will allot an appropriate amount of resources and time for proper messaging and training.

After implementation, providers should ensure that any Health First Colorado member due to receive any of the following PADs have an approved PA on file prior to administration.

Drug Class	HCPCS	Drug Name
Bone Resorption Inhibitor Agents	J0897	Prolia
		Xgeva
Immune Globulin Agents	J1459	Privigen
	J1556	Bivigam
	J1557	Gammaplex
	J1561	Gammaked
		Gamunex
		Gamunex-C
	J1566	Gammagard S/D
	J1568	Octagam 5%, 10%
	J1569	Gammagard Liquid
	J1572	Flebogamma DIF
J1599	Asceniv	
	Panzyga	
Monoclonal Antibody Agents	J0517	Fasenra
	J1300	Soliris
	J1745	Remicade
	J2182	Nucala
	J2357	Xolair
	J2786	Cinqair
	J3380	Entyvio
Multiple Sclerosis Agents	J2323	Tysabri
	J2350	Ocrevus
Neuromuscular Agents	J0585	Botox
	J0586	Dysport
	J0587	Myobloc

Drug Class	HCPCS	Drug Name
	J0588	Xeomin

All PAD PA procedures and clinical criteria will be found on [Appendix Y: Physician Administered Drug Medical Benefit Prior Authorization Procedures and Criteria](#) when a specific date of implementation is available.

Keystone Peer Review Organization (Kepro) will offer various training sessions to providers within the coming months. Additional information will be sent via email, newsletters and monthly provider bulletins and posted to the [ColoradoPAR: Health First Colorado Prior Authorization Request Program](#) and [Physician Administered Drug Provider Resources web page](#).

All other PAD questions can be directed to HCPF_PAD@state.co.us.

Physician Services

Upcoming Diabetes Webinar Opportunity

Join a 30-minute Zoom webinar to learn more about connecting members with diabetes prevention and management programs:

- Evidence behind these programs
- Who qualifies to participate
- Insurance coverage of these programs
- Referring members

Click on a link below to register.

- [Wednesday, December 1](#) (7:30 a.m.-8:00 a.m. MT)
- [Tuesday, December 7](#) (5:00 p.m.-5:30 p.m. MT)
- [Thursday, December 16](#) (12:30 p.m.-1:00 p.m. MT)



There are **two evidence-based programs** that can help support members with diabetes and prediabetes:

- **Diabetes Self-Management Education and Support (DSMES)** is a trusted, covered way to help members self-manage diabetes. DSMES is a Health First Colorado covered benefit.
 - [DSMES Info Sheet](#)
 - [DSMES FAQs](#)
- **The National Diabetes Prevention Program (National DPP)** is proven to help prevent or delay the diagnosis of prediabetes through healthy lifestyle changes.
 - [National DPP Program Info](#)
 - [CDC's National DPP Website](#)

These programs are provided by Colorado's Diabetes Stakeholder Group, working to increase awareness among healthcare providers of programs that can help support patients living with diabetes and prediabetes.

Radiology and Imaging

Temporary Removal of Prior Authorization Requests for Specific Diagnostic Imaging Codes

To reduce the burden on healthcare providers during the public health emergency caused by SARS COVID-19, prior authorization requests for the following codes were temporarily suspended effective November 2, 2021:

74150	74160	74170	74174
74175	74176	74177	74178
72191	72193	72194	

Contact Justen Adams at Justen.Adams@state.co.us with any questions.

Provider Billing Training Sessions

December 2021 and January 2022 Provider Billing Webinar-Only Training Sessions

Providers are invited to participate in training sessions for an overview of Health First Colorado billing instructions and procedures. The current and following months' workshop calendars are shown below.

Who Should Attend?

Staff who submit claims, are new to billing Health First Colorado services, or need a billing refresher course should consider attending one or more of the following provider training sessions.

The institutional claims (UB-04) and professional claims (CMS 1500) training sessions provide high-level overviews of claim submission, prior authorizations, navigating the [Department's website](#), using the [Provider Web Portal](#), and more. For a preview of the training materials used in these sessions, refer to the Beginner Billing Training: Professional Claims (CMS 1500) and Beginner Billing Training: Institutional Claims (UB-04) available on the [Provider Training web page](#) under the Billing Training - Resources drop-down section.

For more training materials on navigating the Provider Web Portal, refer to the Provider Web Portal Quick Guides available on the [Quick Guides web page](#).

Note: Trainings may end prior to 11:30 a.m. MT. Time has been allotted for questions at the end of each session.

December 2021

Sunday	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
			1	2 Beginner Billing Training: Professional Claims (CMS 1500) 9:00 a.m. - 11:30 a.m. MT	3	4
5	6	7	8	9	10	11
12	13	14	15	16 Beginner Billing Training: Institutional Claims (UB-04) 9:00 a.m. - 11:30 a.m. MT	17	18
19	20	21	22	23	24 Christmas Day (observed)	25 Christmas Day
26	27	28	29	30	31 New Year's Day (observed)	

January 2022

Sunday	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
						1 New Year's Day
2	3	4	5	6	7	8
9	10	11	12	13 Beginner Billing Training: Professional Claims (CMS 1500) 9:00 a.m. - 11:30 a.m. MT	14	15
16	17	18	19	20	21	22
23/30	24/31	25	26	27 Beginner Billing Training: Institutional Claims (UB- 04) 9:00 a.m. - 11:30 a.m. MT	28	29

Live Webinar Registration

Register for a live webinar by clicking the title of the desired training session in the calendar above and completing the webinar registration form. An automated response will confirm the reservation. For questions or issues regarding webinar registration, email co.training@gainwelltechnologies.com with the subject line "Webinar Help." Include a description of the issue being experienced, name and contact information (email address and phone number), and the name and date of the webinar(s) to be attended. Allow up to 2-3 business days to receive a response.

Upcoming Holidays

Holiday	Closed Offices/Offices Open for Business
<p>Christmas Day Saturday, December 25 (Observed Friday, December 24)</p>	<p>State Offices, DentaQuest, Gainwell Technologies and the ColoradoPAR Program will be closed. Capitation cycles may potentially be delayed. The receipt of warrants and EFTs may potentially be delayed due to the processing at the United State Postal Service or providers' individual banks.</p>
<p>New Year's Day Saturday, January 1 (Observed Friday, December 31)</p>	<p>State Offices, DentaQuest, Gainwell Technologies and the ColoradoPAR Program will be closed. Capitation cycles may potentially be delayed. The receipt of warrants and EFTs may potentially be delayed due to the processing at the United State Postal Service or providers' individual banks.</p>
<p>Martin Luther King Jr. Day, Monday, January 17</p>	<p>State Offices and the ColoradoPAR Program will be closed. Capitation cycles may potentially be delayed. The receipt of warrants and EFTs may potentially be delayed due to the processing at the United State Postal Service or providers' individual banks. Gainwell Technologies and DentaQuest will be open.</p>

Gainwell Technologies Contacts

Provider Services Call Center
1-844-235-2387

Gainwell Technologies Mailing Address
P.O. Box 30
Denver, CO 80201